Leveraging one of the world’s largest collections of amyloid peptides, AnaSpec has introduced its latest development in novel solutions for amyloid-related research - the new SensoLyte™ 520 Beta-Secretase Assay Kit.
Beta-secretase catalyzes a key step in the production of beta-amyloid peptides seen accumulated in senile plagues of Alzheimer’s disease (AD) brains. In order to facilitate high throughput screening of AD drug candidates, we have developed a new SensoLyte™ 520 beta-secretase assay kit using a fluorescence resonance energy transfer (FRET) peptide, HiLyte Fluor™ 488-Glu-Val-
This assay has good sensitivity (0.03 mU/ml) with a signal-to-background ratio >10 after a 30-minute incubation. This homogeneous assay can be used to continuously monitor product formation. Validated with known inhibitors, the IC50 value for one of the inhibitors determined with SensoLyte™ 520 beta-secretase assay kit was consistent with published data.
Fore more information, visit http://www.anaspec.com/
Company Info
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies:
For more information, visit www.anaspec.com
References:
1. Selkoe DJ. Nature 399: A23 (1999).
2. Suzuki, N., et al. Science 264, 1336 (1994).
3. Iwatsubo, T. et al. Neuron 13, 45 (1994).
4. Qi-Takahara, Y. et al. J. Neurosci. 25, 436 (2005).
5. Zhao, G. et al. J. Biol. Chem. 280, 37689 (2005).
6. Mullan, M. et al. Nat.Genet. 1, 345 (1992).
